Canaccord Genuity Reiterates a 'Buy' on Omeros Corp. (OMER); Key Takeaways From Expert Call Indicate Significant Market Opportunity

January 26, 2011 12:42 PM EST
Get Alerts OMER Hot Sheet
Price: $9.21 +2.91%

Rating Summary:
    10 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 19 | Down: 19 | New: 13
Trade OMER Now!
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Omeros Corp. (NASDAQ: OMER), PT $13.

Canaccord analyst says, "We recently hosted a call with a Dr. William Garrett, a leading orthopaedic surgeon, for an in-depth discussion of Omeros’s Phase 3 PharmacoSurgery program, with a focus on OMS103HP; we expect Phase 3 data in Q1/11. While the initial indication is arthroscopic anterior cruciate ligament (ACL) and meniscectomy, our expert believes that if positive, OMS103HP could enjoy use in other arthroscopic and other surgeries where pain and inflammation are issues."

For more ratings news on Omeros Corp. click here and for the rating history of Omeros Corp. click here.

Shares of Omeros Corp. closed at $7.03 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment